On May 16, Glucotrack received a Nasdaq delisting notice for failing to maintain a minimum bid price of $1.00 and the $2.5 million stockholders' equity requirement. The company intends to request a hearing by May 18, 2026, which would temporarily stay the delisting process.
The company targets over 10% annual revenue growth through 2030 and plans to launch its next-generation G8 glucose monitor by late 2027.
Read the full storyVivos Therapeutics delays its Q1 2026 Form 10-Q filing to consolidate data from its acquisition of The Sleep Center of Nevada, expecting a wider net loss.
The company plans to raise $1.79 million through a direct offering of stock and warrants to support its subsidiary and accelerate its strategic shift toward physical AI.
Glucotrack received a delisting notice for failing to meet the $1.00 minimum bid price and equity requirements, with plans to request a hearing to stay the process.